PortfoliosLab logoPortfoliosLab logo
SEER vs. GANX
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

SEER vs. GANX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Seer, Inc. (SEER) and Gain Therapeutics, Inc. (GANX). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, SEER achieves a -7.65% return, which is significantly higher than GANX's -45.96% return.


SEER

1D
-2.31%
1M
-5.59%
YTD
-7.65%
6M
-8.15%
1Y
-14.21%
3Y*
-27.42%
5Y*
-44.99%
10Y*

GANX

1D
-1.69%
1M
-2.25%
YTD
-45.96%
6M
-45.96%
1Y
-2.79%
3Y*
-27.15%
5Y*
-30.04%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

SEER vs. GANX - Yearly Performance Comparison


2026 (YTD)20252024202320222021
SEER
Seer, Inc.
-7.65%-20.78%19.07%-66.55%-74.57%-58.32%
GANX
Gain Therapeutics, Inc.
-45.96%49.07%-33.84%4.31%-42.36%-51.60%

Correlation

The correlation between SEER and GANX is 0.17, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.17

Correlation (3Y)
Calculated over the trailing 3-year period

0.15

Correlation (5Y)
Calculated over the trailing 5-year period

0.21

Correlation (All Time)
Calculated using the full available price history since Mar 18, 2021

0.21

Fundamentals

Market Cap

SEER:

$94.63M

GANX:

$73.48M

EPS

SEER:

-$1.24

GANX:

-$0.60

PB Ratio

SEER:

0.39

GANX:

5.25

Total Revenue (TTM)

SEER:

$15.17M

GANX:

$0.00

Gross Profit (TTM)

SEER:

$7.39M

GANX:

$2.13M

EBITDA (TTM)

SEER:

-$63.20M

GANX:

-$19.59M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Seer, Inc.

Gain Therapeutics, Inc.

Often compared with SEER:
SEER vs. CRON

Return for Risk

SEER vs. GANX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SEER
SEER Risk / Return Rank: 2828
Overall Rank
SEER Sharpe Ratio Rank: 2828
Sharpe Ratio Rank
SEER Sortino Ratio Rank: 2727
Sortino Ratio Rank
SEER Omega Ratio Rank: 2727
Omega Ratio Rank
SEER Calmar Ratio Rank: 2727
Calmar Ratio Rank
SEER Martin Ratio Rank: 2828
Martin Ratio Rank

GANX
GANX Risk / Return Rank: 4646
Overall Rank
GANX Sharpe Ratio Rank: 4242
Sharpe Ratio Rank
GANX Sortino Ratio Rank: 5252
Sortino Ratio Rank
GANX Omega Ratio Rank: 5353
Omega Ratio Rank
GANX Calmar Ratio Rank: 4141
Calmar Ratio Rank
GANX Martin Ratio Rank: 4242
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SEER vs. GANX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Seer, Inc. (SEER) and Gain Therapeutics, Inc. (GANX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


SEERGANXDifference
Sharpe ratioReturn per unit of total volatility

-0.31

Sortino ratioReturn per unit of downside risk

-1.04

Omega ratioGain probability vs. loss probability

0.97

1.11

-0.14

Calmar ratioReturn relative to maximum drawdown

-0.48

-0.05

-0.43

Martin ratioReturn relative to average drawdown

-0.79

-0.07

-0.71

SEER vs. GANX - Sharpe Ratio Comparison

The current SEER Sharpe Ratio is -0.34, which is lower than the GANX Sharpe Ratio of -0.03. The chart below compares the historical Sharpe Ratios of SEER and GANX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

SEER vs. GANX - Drawdown Comparison

The maximum SEER drawdown since its inception was -98.25%, roughly equal to the maximum GANX drawdown of -94.08%. Use the drawdown chart below to compare losses from any high point for SEER and GANX.


Loading charts...

Drawdown Indicators


SEERGANXDifference

Max Drawdown

Largest peak-to-trough decline

-98.25%

-94.08%

-4.17%

Max Drawdown (1Y)

Largest decline over 1 year

-29.96%

-61.96%

+32.00%

Max Drawdown (3Y)

Largest decline over 3 years

-73.37%

-81.43%

+8.06%

Max Drawdown (5Y)

Largest decline over 5 years

-96.74%

-91.13%

-5.61%

Current Drawdown

Current decline from peak

-97.99%

-88.99%

-9.00%

Average Drawdown

Average peak-to-trough decline

-86.24%

-75.53%

-10.71%

Ulcer Index

Depth and duration of drawdowns from previous peaks

18.06%

37.72%

-19.66%

Volatility

SEER vs. GANX - Volatility Comparison

The current volatility for Seer, Inc. (SEER) is 9.81%, while Gain Therapeutics, Inc. (GANX) has a volatility of 21.50%. This indicates that SEER experiences smaller price fluctuations and is considered to be less risky than GANX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


SEERGANXDifference

Volatility (1M)

Calculated over the trailing 1-month period

9.81%

21.50%

-11.69%

Volatility (6M)

Calculated over the trailing 6-month period

33.49%

69.90%

-36.41%

Volatility (1Y)

Calculated over the trailing 1-year period

42.38%

110.23%

-67.85%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

73.71%

86.14%

-12.43%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

77.24%

85.14%

-7.90%

Dividends

SEER vs. GANX - Dividend Comparison

Neither SEER nor GANX has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

SEER vs. GANX - Financials Comparison

This section allows you to compare key financial metrics between Seer, Inc. and Gain Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.001.00M2.00M3.00M4.00M20222023202420252026
2.79M
0
(SEER) Total Revenue
(GANX) Total Revenue
Values in USD except per share items

Frequently Asked Questions


SEER and GANX have a correlation of 0.17, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

GANX has higher volatility (21.50%) compared to SEER (9.81%). In terms of maximum drawdown, SEER dropped -98.25% vs GANX's -94.08%.

GANX currently has the higher Sharpe Ratio (-0.03 vs -0.34), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for SEER and GANX

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer